Exemestane (Aromasin) and letrozole ( Femara) listings extended to early breast cancer in postmenopausal womenExemestane (Aromasin) and letrozole ( Femara) listings extended to early breast cancer in postmenopausal women

Published 2006-12-01 00:00:00

The PBS restriction for two aromatase inhibitors, exemestane and letrozole, was extended on 1 December 2006 to include adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women. These drugs were previously listed as restricted benefits for advanced breast cancer only — the new listings bring them into line with anastrozole (Arimidex), which is also available on the PBS for early breast cancer [refer to the NPS RADAR review "Anastrozole (Arimidex) for the treatment of hormone-dependent early breast cancer in postmenopausal women" (December 2005 issue)].

Exemestane may be prescribed on the PBS for hormone-dependent early breast cancer after a minimum of 2 years' treatment with tamoxifen. Letrozole may be prescribed as initial adjuvant hormonal treatment or be started after 2-3 years of tamoxifen.1 The total duration of PBS-subsidised adjuvant hormonal treatment with an aromatase inhibitor (or with tamoxifen followed by an aromatase inhibitor) should not exceed 5 years.

References

  1. National Breast Cancer Centre (NBCC). Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. Clinical Practice Guideline. Camperdown: NBCC, 2006. http://www.nbcc.org.au/bestpractice (accessed 18 October 2006).
RSS FeedRSS feed

Date published: 2006-12-01 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.